Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xuefeng Yin

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Arthritis Research & Therapy|May 4, 2018
Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosusSuzanne Cole, Alice Walsh, Xuefeng Yin, et al.
Journal of Medicinal Chemistry|October 27, 2006
Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activityXin-Jie Chu, Wanda DePinto, David Bartkovitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2013
RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune responseXuefeng Yin, Leopoldo Luistro, Hua Zhong, et al.
Plos One|March 1, 2018
Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progressionYanxia Guo, Alice M Walsh, Mary Canavan, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Arthritis Research & Therapy|May 4, 2018
Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosusSuzanne Cole, Alice Walsh, Xuefeng Yin, et al.
Journal of Medicinal Chemistry|October 27, 2006
Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activityXin-Jie Chu, Wanda DePinto, David Bartkovitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2013
RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune responseXuefeng Yin, Leopoldo Luistro, Hua Zhong, et al.
Plos One|March 1, 2018
Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progressionYanxia Guo, Alice M Walsh, Mary Canavan, et al.
Pageof 7